Tricida, Inc. (TCDA)

$ 4.595
-0.18 (-3.67%)
-
Symbol TCDA
Price $ 4.595
Beta 1.222
Volume Avg. 0.22M
Market Cap 0.23B
Shares () -
52 Week Range 3.55-9.29
1y Target Est -
DCF Unlevered TCDA DCF ->
DCF Levered TCDA LDCF ->
ROE -180.09% Strong Sell
ROA -84.56% Strong Sell
Operating Margin -
Debt / Equity 458.13% Strong Buy
P/E -
P/B 6.62 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest TCDA news


Dr. Gerrit Klaerner
Healthcare
Biotechnology
Nasdaq Global Select

Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). The company has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California.